



**This document was valid from 5 June 2008 until May 2020.
It is now superseded by a [new version](#) adopted by the HMPC on
6 May 2020 and published on the EMA website.**

LIST OF REFERENCES SUPPORTING THE ASSESSMENT ON:

**Rhamni purshianae cortex
Rhamnus purshianus D.C.
(Cascara)**

The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

In the Assessment Report the references having been referred with numbers.

1. German monograph of Rhamni purshianae cortex (Amerikanische Faulbaumrinde), BanzNr. 133 vom 21.07.1993
2. Bundesinstitut für Arzneimittel und Medizinprodukte. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln – Abwehr von Arzneimittelrisiken, Stufe II – Humanarzneimitteln zur innerlichen Anwendung, ausgenommen nach HAB 1 hergestellte homöopathische Arzneimittel, welche Drogen, Drogenzubereitungen oder isolierte Inhaltsstoffe der Anthranoid-(Hydroxyanthracenderivat-) haltigen Pflanzengattungen Andira, Cassia, Rhamnus, Rheum oder Aloe enthalten (German pharmacovigilance actions for anthranoide-containing laxatives) vom 21. Juni 1996, Bundesanzeiger vom 05.07.1996 Nr. 123, Seite 7581
3. ESCOP monograph “RHAMNI PURSHIANI CORTEX” (Cascara), 2nd edition 2003, Thieme Verlag Stuttgart, New York
4. Tarpila S et al. Efficacy of ground flaxseed on constipation in patients with irritable bowel syndrome. *Cur.Top.Nutr. Res.*2004; 2: 119-25
5. Goodman & Gilman’s. The Pharmacological Basis of Therapeutics. Eleventh edition. Section VI / Drugs affecting gastrointestinal function. Stimulant (Irritant) Laxatives
6. HagerROM 2003, Springer Verlag, Heidelberg: Rhamni purshiani cortex (Cascara)
7. Fairbairn JW et al. Cascariosides A and B. *Journal of pharmaceutical sciences* 1977; Vol 66 (9): 1300-3
8. Griffini A et al. Isolation and characterization of pure cascariosides A, B, C, and D. *Planta Medica* 1992; Vol 58 (7): A593-A594

9. Manitto P et al. Studies on cascara, Part 2. Structures of cascarosides E and F. *J. Nat.Prod.* 1995; Vol 58 (3): 419-23
10. Van Os FHL. Anthraquinones derivatives in vegetable laxatives. *Pharmacology* 1976; 14 (suppl 1): 7-17
11. Submission of a review of data from the national toxicology program and relevant to the status of cascara sagrada ingredients as over-the counter drug active ingredients by the American herbal products association, December 19, 2002, Docket No. 78N-036L
12. Lang W. Pharmacokinetic-metabolic studies with ¹⁴C-aloe emodin after oral administration to male and female rats. *Pharmacology* 1993; 47 (Suppl 1): 110-9
13. Liang JW et al. Emodin pharmacokinetics in rabbits. *Planta medica* 1995; Vol 61 (5): 406-8
14. Capasso F et al. Effect of indomethacin on aloin and 1,8 dioxianthraquinone-induced production of prostaglandins in rat isolated colon. *Prostaglandins* 1983; 26 (4): 557-62
15. Cohen MM. The effect of cathartics on prostaglandin synthesis by rat gastro-intestinal tract. *Prostaglandins, leukotrienes, and medicine* 1982; Vol 8 (4): 389-97
16. Izzo AA et al. NG-nitro-L-arginine methyl ester reduces senna- and cascara-induced diarrhoea and fluid secretion in the rat. *Eur. J. pharmacol.* 1996; 301 (1-3): 137-42
17. Izzo AA et al. The role of constitutive and inducible nitric oxide synthase in senna- and cascara-induced diarrhoea in the rat. *Eur. J. pharmacol* 1997; 323 (1): 93-7
18. Dreessen M, Lemli J. Studies in the field of drugs containing anthraquinone derivatives. XXXVI. The metabolism of cascarosides by intestinal bacteria. *Pharm. Acta Helv* 1988; 63 Nr. 9-10: 287-9
19. De Witte P, Lemli L. The metabolism of anthranoid laxatives. *Hepato-gastroenterology* 1990; 37 (6): 601-5
20. Müller SO et al. Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites. *Drug metabolism and disposition: the biological fate of chemicals* 1998; 26 (6): 540-6
21. NTP Technical Report on the Toxicology and Carcinogenesis Studies of Emodin in F344/N Rats and B6C3F₁ Mice. National Toxicology Programm, June 2001, NTP TR 493, NIH Publication No. 01-3952
22. Masuda T et al. 2-Hydroxyemodin, an active metabolite of emodin in the hepatic microsomes of rats. *Mutation Res.* 1985; 149: 327-332
23. Mengs U et al. Lack of emodin genotoxicity in the mouse micronucleus assay. *Mutation Res.* 1997; 393: 289-93
24. Jahnke GD et al. Developmental toxicity evaluation of emodin in rats in mice. *Birth Defects Research Part B – Develop. Reprod. Toxicol.* 2004; 71 (2): 89-101

25. Heidemann a et al. Genotoxicity of aloemodin in vitro and in vivo. *Mutation Res.* 1996; 367: 123-3
26. Schörkhuber M et al. Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells. *European journal of cancer: official journal for European Organisation for Research and Treatment of Cancer (EORTC) (and) European Association for Cancer Research (EACR)* 1998; 34 (7): 1091-8
27. Siegers CP et al. Sennosides and aloin do not promote dimethylhydrazine-induced colorectal tumors in mice. *Pharmacology* 1993; 47, No.1: 205-8
28. Mereto E et al. Evaluation of the potential carcinogenic activity of senna and cascara glycosides for the rat colon. *Cancer Let.* 1996; 101 (1): 79-83
29. Borelli F et al. Effect of bisacodyl and cascara on growth of aberrant crypt foci and malignant tumors in the rat colon. *Life Scie.* 2001; 69 (16): 1871-7
30. Vyth A and Kamp PE. Detection of anthraquinone laxatives in the urine. *Pharm Weekbl SCI ED* 1979; No.2: 456-59
31. Ewe K. Obstipation und Laxanzien. *Dtsch. Apoth. Ztg.* 1994; 134: 825-33
32. Gabler F. Obstipation und Laxanzien. *PTA heute* 8,1994, 5, 380-8
33. Tavares IA et al. Effects of anthraquinone derivatives on PAF release by human gastrointestinal mucosa in vitro. *Phytotherapy Research* 1996; 10 (Suppl.1): S20-S21
34. Izzo AA et al. Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. *Trends in pharmacological sciences* 1998; 19 (10): 403-5
35. Koch A. Aloe als Laxans: ein neues Argument für die Überprüfung der Droge (Aloe as a laxative: a new argument for the investigation of the drug). *Dtsch Apoth Ztg* 1995; 135 (12): 29-32
36. Mueller SO et al. Occurrence of emodin, chrysophanol and physcion in vegetables, herbs and liquors. Genotoxicity and anti-genotoxicity of the anthraquinones and of the whole plants. *Food Chem. Toxicol.* 1999; 37: 481-91
37. Che QM et al. Isolation of a human intestinal bacterium capable of transforming barbaloin to aloë-emodin anthrone. *Planta Medica* 1991; 57 (1): 15-9
38. Yagi T, Yamauchi K. Synergistic effects of anthraquinones on the purgative activity of rhein anthrone in mice. *J. Pharm.Pharmacol.*1999; 51 (1): 93-5
39. Stern FH. Constipation – an omnipresent symptom: effect of a preparation containing prune concentrate and cascarn. *J. Am. Geriatr.Soc.* 1966; 14 (11): 1153-5
40. Mauracher R et al. Gekreuzter Doppelblindvergleich von gereinigtem Glucofrangulin mit zwei anderen Laxantien. Comparison of glucofrangulin in purified form with two other laxatives. *Praxis* 1976; 65 (21): 655-8
41. Borgia M et al. A double-blind double-controlled multicenter study of the therapeutic efficacy of a well-known combination of medicinal herbs. *Clin Ter* 1985; 114 (5): 401-9

42. Foert E et al. Cascara stimulates gallbladder contraction: a randomised placebo-controlled double-blind trial. *Gastroenterology* 1994; 106 (4 Suppl): A338
43. Wicke L. Zur Darmreinigung vor Irrigoskopien. Bowel cleansing before irrigoscopy. *Wiener medizinische Wochenschrift* 1981; 131 (5): 133-4
44. Novetsky GJ et al. Cleansing the colon in gallium-67 scintigraphy: a prospective comparison of regimens. *AJR Am. J. Roentgenol.*1981; 137 (5): 979-81
45. Fork FT. Colon cleansing regimens. *Gastrointest Radiol* 1982; 7: 383-9
46. Hangartner PJ et al. Comparison of three colon cleansing methods: evaluation of a randomised clinical trial with 300 ambulatory patients. *Endoscopy* 1989; 21: 272-5
47. Phillip J et al. Vorbereitung zur Koloskopie mit "Golytely" – eine sichere Methode? Vergleichende histologische und klinische Untersuchung zwischen Lavage und salinischem Laxans. Preparation for colonoscopy using Golytely – a sure method? Comparative histological and clinical study between lavage and saline laxatives. *Medizinische Klinik* 1990; 85 (7): 415-20
48. Børkje B et al. Effectiveness and acceptability of three bowel cleansing regimes. *Scand. J. Gastroenterol.*1991; 26 (2): 162-6
49. D'Angelo L: Effects of cascariosides and their metabolites on colonic intestinal muscle. *Acta Toxicol. Therap.* 1993; 14 (3): 193-7
50. Williams CL et al. A summary of conference recommendations on dietary fiber in childhood: Conference on Dietary Fiber in Childhood, New York (New York, USA), May 24, 1994. *Pediatrics* 1995; 96: 1023-28
51. HagerROM 2003, Springer Verlag, Heidelberg: Frangulae cortex (Faulbaumrinde) (Like ref 6)
52. Faber P et al. Relevance of rhein excretion into breast milk. *Pharmacology* 1988; 36 (Suppl 1) 212-20
53. Heidemann A et al. The Genotoxicity Status of Senna. *Pharmacology* 1993; 47, Suppl. 1: 178-186
54. Sitzmann FC et al. Lokale Nebenwirkungen an der Haut durch Anthraglykoside. *Pädiatr Prax* 1979; 21: 355-8
55. Beuers U et al. Hepatitis after chronic abuse of senna. *Lancet (England)* 1991; Vo.: 337: 372-373 (Senna reference 91)
56. Vanderperren B et al. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. *Ann Pharmacotherapy* 2005; 39: 1353-7 (Senna reference 122)
57. Müller-Lissner S. Myths and misconceptions about chronic constipation. *Am J Gastroenterol* 2005; 100: 232-42 (corresponding to senna reference 111)
58. Smith B. Effect of irritant purgatives on the myentric plexus in man and mouse. *Gut* 1968; 9: 139-45 (corresponding to senna reference 112)

59. Riemann JF et al. The fine structure of colonic submucosal nerves in patients with chronic laxative abuse. *Scand J Gastroenterol* 1980; 15: 761-8 (corresponding to senna reference 113)
60. Riemann JF et al. Ultrastructural changes in the gut autonomic nervous system following laxative abuse and in other conditions. *Scand J Gastroenterol* 1982; 71: 11-24 (corresponding to senna reference 114)
61. Berkelhammer C et al. Low-volume oral colonoscopy bowel preparation: sodium phosphate and magnesium citrate. *Gastrointest Endosc* 2002; 56: 89-94 (corresponding to senna reference 115)
62. Meisel JL et al. Human rectal mucosa: proctoscopic and morphological changes caused by laxatives. *Gastroenterology* 1977; 72: 1274-9 (corresponding to senna reference 116)
63. Pockros PJ et al. Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology. *Gastroenterology* 1985; 88: 545-8 (corresponding to senna reference 117)
64. Riecken EO et al. The effect of an anthraquinone laxative on colonic nerve tissue: A controlled trial in constipated women. *Z Gastroenterol* 1990; 28: 660-4 (corresponding to senna reference 118)
65. Danan G and Benichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiology* 1993; Vol 46 (11):1323-30
66. Benichou C et al. Causality assessment of adverse reactions to drugs – II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. *J Clin Epidemiology* 1993; Vol.46 (11): 1331-36
67. Nadir A et al. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. *Am.J. Gastroenterology* 2000; 95 (1): 3634-7
68. Adesunloye BA Acute renal failure due to herbal remedy CKLS. *Am.J. Med.*2003; 115: 506-7
69. Madaus G. *Lehrbuch der Biologischen Heilmittel*, Band I, Georg Thieme Verlag, Leipzig 1938
70. *The British Pharmaceutical Codex*, published by direction of the Council of the Pharmaceutical Society of Great Britain, 1911.
71. *The Eclectic Materia Medica, Pharmacology and Therapeutics*, by Harvey Wickes Felton, M.D., 1922
72. *Hagers Handbuch der Pharmazeutischen Praxis*, Dr. G. Frerichs, G. Arends, Dr. H. Zörnig (Herausgeber), 2. Band: 558 – 63, Berlin, Verlag von Julius Springer 1927
73. *Martindale – The Extra Pharmacopoeia – 25th ed* 1967. RG Todd (editor). London. The pharmaceutical press
74. Dragendorff G. *Die Heilpflanzen der verschiedenen Völker und Zeiten*. Werner Fritsch, München 1967
75. *The Dispensatory of the United States of America*, edited by Joseph P. Remington, Horatio C. Wood and others, 1918

76. Giavina-Bianchi Jr PF et al. Occupational respiratory allergic disease induced by *Passiflora alata* and *Rhamnus purshiana*. *Ann.Allergy, Asthma & Immunol.* 1997; 79: 449-54
77. Schmidt L. Vergleichende Pharmakologie und Toxikologie der Laxantien. *Arch Exper Path Pharmacol* 1955; 226: 207-18
78. Konsensuspapier Expertenforum: Obstipation und Laxanzien. *Praxis* 1999; 88: 1269-74 (corresponding to senna reference 104)
79. De Witte P; Lemli J: Metabolism of ¹⁴C-rhein and ¹⁴C-rhein anthrone in rats. *Pharmacology* 1988; 36 (Suppl 1): 152-7
80. Westendorf J et al. Genotoxicity of naturally occurring hydroxyanthraquinones. *Mutat Res* 1990; 240: 1-12
81. Helmholz H et al. Genotoxizität der Faulbaumrinde. Genotoxicity of buckthorn bark. *Pharmaz. Zeit.*1993; 138 (Oct 28): 48-50
82. Steinegger. *Pharmakognosie – Phytopharmazie*, Springer Verlag 7. Auflage
83. Siegers C-P et al. Anthranoid laxative abuse – A risk for colorectal cancer? *Gut* 1993; 34 (8): 1099-101 (corresponding to Frangula 41)
84. Kune GA et al. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer. Data from the Melbourne Colorectal Cancer Study. *Diseases of the colon and rectum* 1988; 31 (7): 507 – 12 (corresponding to Frangula 42)
85. Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. *Zeitschrift für Gastroenterologie* 1993; 31 (2): 140-3 (corresponding to Frangula 43)
86. Nusko G et al. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma. *Pharmacology* 1993; 47 Suppl 1: 234-41 (corresponding to Frangula 44)
87. Sonnenberg A, Muller AD. Constipation and cathartics as risk factors of colorectal cancer: A meta-analysis. *Pharmacology* 1993; 47 (Suppl.): 224-33 (corresponding to Frangula 45)
88. Loew D et al. Anthranoid laxatives: cause of colorectal cancer? *Deutsche Apotheker-Zeitung* 1994; 134 (Aug 25): 30, 32-33 (corresponding to Frangula 46)
89. Jacobs EJ et White E. Constipation, laxative use, and colon cancer among middle-aged adults. *Epidemiology* 1998; 9: 385-91 (corresponding to senna reference 109)
90. Nusko G et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. *Gut* 2000; 46: 651-55 (corresponding to Frangula 47)
91. Roberts MC et al. Constipation, laxative use, and colon cancer in a North Carolina population. *Am J Gastroenterol* 2003; 98: 857-64 (corresponding to senna reference 110)
92. Nilsson SE et al. Laxative treatment elevates plasma homocysteine: A study on a population-based Swedish sample of old people. *European Journal of Clinical Pharmacology* 2004; 60 (1): 45-49 (corresponding to Frangula 49)

93. Jae Sik Joo et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: The cathartic colon revisited. *J. Clin. Gastroenterology* 1998; 26 (4): 283-6 (corresponding to Frangula 50)
94. Van Gorkom BA et al. Review article: anthranoid laxatives and their potential carcinogenic effects. *Alim. Pharmacol. & Therap.* 1999; 13 (4): 443-52 (corresponding to Frangula 51)
95. Willems M et al. Anthranoid self-medication causing rapid development of melanosis coli. *Netherl. J. Med.* 2003; 61 (1): 22-4 (corresponding to Frangula 48)

Superseded